Perkins Coie Represents Pacira BioSciences in Acquisition of Flexion Therapeutics

DENVER (October 13, 2021)—Perkins Coie is pleased to represent Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, in connection with its publicly announced definitive agreement to acquire Flexion Therapeutics, Inc., subject to customary closing conditions, including receipt of required regulatory approvals. For more information, please see Pacira's press release here.

Under the terms of the deal, Pacira will acquire Flexion for $8.50 per share in cash, plus one non-tradeable contingent value right (CVR) worth up to $8.00 per share in cash. Flexion's innovative non-opioid portfolio directly aligns with Pacira's mission to provide an opioid alternative to as many patients as possible and address medical needs along the neural pain pathway. Flexion is focused on the development and commercialization of novel, local non-opioid therapies for the treatment of patients with musculoskeletal conditions, including osteoarthritis, postsurgical pain, and low back pain.

The Perkins Coie deal team representing Pacira BioSciences in the transaction is led by Denver partners Jason Day and Jeff Beuche, counsel Jonathan Schulman and David Martinez.